cas 4442-54-0|| where to buy 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid

Nombre del producto:2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid

IUPAC Name:2,3-dihydro-1,4-benzodioxine-6-carboxylic acid

Unidad de embalaje	Stock disponible	Precio($)
CM158112-25g	in stock	şœ
CM158112-100g	in stock	ƅƅǺ
CM158112-500g	in stock	ƏŭȤƅ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4442-54-0 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :4442-54-0; Fórmula molecular:C9H8O4; Punto de fusión:-; Código de sonrisas:O=C(C1=CC=C(OCCO2)C2=C1)O; Densidad:

: Número de catálogo:CM158112; Peso molecular:180.16; Punto de ebullición:339.8°C at 760 mmHg; Nº Mdl:MFCD00463509; Almacenamiento:Store at room temperature.

: Benzodioxanes; Benzodioxanes are a class of isomeric compounds with the molecular formula C8H8O2. The three isomers of benzodioxane are 1,2-benzodioxane, 1,3-benzodioxane and 1,4-benzodioxane. 1,4-Benzodioxane has long been a versatile template widely used to design molecules with diverse biological activities. Its use spans past decades in medicinal chemistry to today, involving many drug discovery strategies, not excluding the most advanced ones. 1,4-Benzodioxane derivatives have been described as agonists and antagonists of nicotinic, alpha-adrenergic and 5-HT receptor subtypes. 1,4-Benzodioxane derivatives have been also reported as antitumor and antibacterial agents.

: NXP800; Nuvectis Pharma announces encouraging preliminary data from the NXP800 phase 1b clinical trial in platinum-resistant ARID1a-mutated ovarian cancer. There is a 33% response rate and 100% disease control rate in patients evaluated for efficacy.
Heat shock transcription factor 1 (HSF1) is critical for tumorigenesis and progression, and is implicated in multiple solid tumors. NXP800 is a potent, clinical stage inhibitor of the HSF1 pathway. The compound activates GCN2 kinase, that phosphorylates the eIF2α and later encodes the ATF4 transcription regulator, resulting in cancer cell death. NXP800 previously gets Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian cancer.